SEATTLE, August 05, 2021, (MEDGADGET) — Global Clostridium Vaccine Market Analysis
The most common cause of hospital-acquired infectious diarrhea is Clostridium difficile infections. The advent of a preventative vaccination for this illness is crucial. Clostridium difficile is a gram-positive bacteria that generates an anaerobic toxin that is passed from person to person via the feces-oral pathway. Clostridium difficile infections can arise as a result of antibiotic therapy or as a result of a healthcare-associated illness, with symptoms ranging from asymptomatic illness to watery diarrhea or cause gastrointestinal conditions including colitis and colonic collapse.
Increasing C. difficile infections in healthcare institutions, as well as antibiotic resistance to treatment medications, are driving the need for preventive solutions to protect susceptible individuals from infection. Clostridium difficile was identified as an urgent antibiotic-resistance problem in the U.S. by the Centers for Disease Control and Prevention (CDC) in a 2013 bulletin.
*The Sample consists of Table of Content, Research framework of the actual report & research methodology adopted for it.
Download Free PDF Sample: https://www.coherentmarketinsights.com/insight/request-pdf/2359
The global clostridium vaccine market is projected to rise due to the rising incidence and high prevalence of Clostridium difficile infection during the forecast period. Due to infection recurrence and antibiotic resistance, the incidence of Clostridium difficile infection has been on the rise in recent years. As per the Centers for Disease Control and Prevention (CDC), almost half a million people in the United States have clostridium difficile infections annually.
As per the National Center for Biotechnology Information (NCBI), 37,900 people in Canada were infected with Clostridium difficile in 2012. A study and meta-analysis of research published in the National Center for Biotechnology Information (NCBI) in 2016 that was conducted in China during 2010 and 2016 found a high prevalence of clostridium difficile infection.
Nowadays, there are no other options for treating clostridium difficile infection other than antibiotics; the only options are surgery (in severe instances), fecal microbiota transplant, and probiotics in the event of recurring clostridium difficile infection.
“Limited Time Offer”
Buy This Research Study Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2359
Furthermore, major pharmaceutical companies are undertaking clinical studies for the production of a clostridium vaccine that might be used to prevent clostridium difficile infection in the near future. Pfizer disclosed a phase II trial of an experimental Clostridium difficile vaccine candidate, PF-06425090, to prevent C. difficile infection in January 2017. The vaccine’s safety, tolerability, and immunogenicity were tested in healthy individuals aged 65 to 85 in this randomized phase II research. In March 2017, Pfizer began a phase III research with approximately 16,000 individuals.
Valneva SE stated in July 2016 that its phase II clinical investigation for its prophylactic vaccine candidate VLA84 aiming early detection of C. difficile infection has been completed successfully (CDI).
Due to the rising number of Clostridium difficile infections in the U.S. and heightened concern about the implementation of preventive measures in Clostridium difficile infection in this region, North America is expected to hold a leading place in the global clostridium vaccine market, accounting for the largest market share during the forecast period.
As per the CDC, C. difficile-related healthcare-associated infections (HAIs) caused roughly half a million illnesses in the U.S. in 2011, with 29,000 people dying within 30 days of their first diagnosis.
To get a detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/2359
Elevated chance of vaccine candidate failure during clinical trial studies, as well as high costs associated with late-stage testing, are projected to hinder clostridium vaccine commercialization and constrain the global clostridium vaccine market expansion during the forecast period. Sanofi halted its phase III C. difficile clinical trial research in December 2017 owing to the findings of an interim trial analysis, which indicated that their C. difficile candidate had a low likelihood of success. The withdrawal of Sanofi’s C. difficile vaccine program is projected to provide Pfizer and Valneva with a significant future chance to deliver their vaccine to patients after receiving good results.
Major companies contributing to the global clostridium vaccine market are Pfizer, Inc., and Valneva SE.
Table of Content
Global Clostridium Vaccine Market Research Report
Section 1: Global Clostridium Vaccine Industry Overview
Section 2: Global Economic Impact on Clostridium Vaccine Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Clostridium Vaccine Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Clostridium Vaccine Market Forecast
Other Exclusive Reports:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027